Dianthus Therapeutics, Inc. (NASDAQ: DNTH - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the thirteen research firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has assigned a strong buy rating

5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus.

NEW YORK and WALTHAM, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the pricing of its previously announced upsized underwritten public offering of 7,313,582 shares of its common stock at a public offering price per share of $81.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 402,468 shares of its common stock at a public offering price of $80.999 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to Dianthus from the offering are expected to be approximately $625 million before deducting underwriting discounts and commissions and other offering expenses and advisory fees payable by Dianthus, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on March 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Dianthus has granted the underwriters a 30-day option to purchase up to an additional 1,157,407 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are being offered by Dianthus.

Dianthus Therapeutics, Inc. is maintained at a Buy rating, supported by strong clinical progress and a 174.53% stock gain since the last update. Claseprubart delivered statistically significant MG-ADL improvements in phase 2 Myasthenia Gravis and is advancing to phase 3, with topline data expected in 2H 2028. An early "GO decision" for the phase 3 CAPTIVATE trial in CIDP, driven by positive interim response rates, sets up a key DNTH catalyst with top-line data release update year-end 2026.

Dianthus Therapeutics, Inc. (DNTH) Discusses Interim Responder Analysis and Early Go Decision for CAPTIVATE Trial in CIDP Transcript

Dianthus Therapeutics stock shot higher Monday after the company said it would advance its experimental CIDP treatment.

Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $1.43 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $0.81 per share a year ago.

CIDP is a rare, acquired autoimmune disorder where the immune system damages the myelin sheath of peripheral nerves, causing progressive or relapsing muscle weakness, numbness, and sensory loss lasting over 8 weeks.

Early GO decision reached in CAPTIVATE ahead of Q2'26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A

NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET.